BioInvent is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with four ongoing programs in phase l/ll clinical trials for the treatment of haematological and solid tumours. Further, two preclinical programs in solid tumours are expected to enter clinical trials before the end of 2022. The company’s validated proprietary F.I.R.S.T technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the company’s own clinical development pipeline or for additional licensing and partnering.
The most material event was the clinical data presented for the lead program of BI-1206 + Rituximab showed partial responses in 6/9 Rituximab refractory/relapsed NHL patients of which two patients became cancer free for 12 & 24 months respectively. Recent deals in the area such as by Novartis and Beigene validated the approach and target of the lead asset. The company also recruited first patients in the phase I/II trial of BI-1206 together with MSD’s pembrolizumab (Keytruda) as well as for BT-001 and BI-1808.
We expect a catalyst-rich period of over the next six months. As enrolment has progressing well, we should get a glimpse on clinical data from all four ongoing clinical trials over the next 6 months. These include BI-1206+Rituximab (NHL) follow-up and dose expansion data, preliminary safety and efficacy data from BI-
1206+Keytruda, BT-001 and BI-1808 (solid tumours).
Please refer to important disclosures here.